The pharmaceutical company Baudax Bio Inc (NASDAQ:BXRX) has had a pretty tough time in the markets over the course of the past month and that has been reflected in the price action in its stock, which has recorded a decline of 14% during the period.
There has been no fresh news about the company in recent day but it might be a good time to take a look at the company’s financial results for the quarter and the six month period that ended on June 30, 2021. The results had been announced by Baudax Bio back on August 5.
The company announced that at the end of the quarter, it had cash, short term investments and cash equivalents to the tune of as much as $37.6 million on its books.
On the other hand, the net revenues generated by the company in the second quarter came in at $0.2 million and that was lower than the $0.3 million that it had generated in the prior year period. It should also be noted that the cost of sales for the period was $0.6 million in the second quarter. In the prior year period, the cost of sales stood at $0.7 million.
